First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes

Background: The objective of this study was to assess the safety and effectiveness of the first commercial configuration of a tubeless automated insulin delivery system, Omnipod(®) 5, in children (6–13.9 years) and adults (14–70 years) with type 1 diabetes (T1D) in an outpatient setting. Materials a...

Descripción completa

Detalles Bibliográficos
Autores principales: Forlenza, Gregory P., Buckingham, Bruce A., Brown, Sue A., Bode, Bruce W., Levy, Carol J., Criego, Amy B., Wadwa, R. Paul, Cobry, Erin C., Slover, Robert J., Messer, Laurel H., Berget, Cari, McCoy, Susan, Ekhlaspour, Laya, Kingman, Ryan S., Voelmle, Mary K., Boyd, Jennifer, O'Malley, Grenye, Grieme, Aimee, Kivilaid, Kaisa, Kleve, Krista, Dumais, Bonnie, Vienneau, Todd, Huyett, Lauren M., Lee, Joon Bok, O'Connor, Jason, Benjamin, Eric, Ly, Trang T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215410/
https://www.ncbi.nlm.nih.gov/pubmed/33325779
http://dx.doi.org/10.1089/dia.2020.0546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215410/
https://www.ncbi.nlm.nih.gov/pubmed/33325779
http://dx.doi.org/10.1089/dia.2020.0546

Ejemplares similares